RxDoctor Payments Data

Francesca van Sant

Nurse Practitioner · Bethesda, MDNPI 1174033500

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $10,057 of the $15,554 with a category attached, or 64.7%. It is spread thinly across 60 manufacturers, the largest accounting for just 18.0%. 2025 is the largest year on record at $5,297, 3.4 times the $1,540 reported in 2021. Among nurse practitioner clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$15,554in general payments, 2019–2025

Across 404 payments — averaging $38.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novartis$2K
  • Fennec Pharmaceuticals, Inc.$2K
  • Johnson & Johnson$1K
  • Merck$478
  • Pfizer$378
  • plus $6K from 54 others

What the payments were for

  • Consulting fees$2,43216%
  • Travel & lodging$1,1888%
  • Food & beverage$10,05765%
  • Education$5974%
  • Other$1,2808%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie23$2,804
Novartis56$2,285
Fennec Pharmaceuticals, Inc.10$1,937
Johnson & Johnson(2 entities)50$1,445
Merck20$478
Pfizer15$378
Daiichi Sankyo Inc.13$336
Rigel Pharmaceuticals, Inc.4$271
Takeda Pharmaceuticals U.S.A., Inc.10$267
Astellas Pharma US Inc8$261
Seagen Inc.13$257
Tempus AI, Inc3$249
Exelixis Inc.7$241
Bristol Myers Squibb9$237
Incyte Corporation7$236
Amgen10$229
Genentech USA, Inc.6$214
AstraZeneca9$213
Sanofi8$185
E.r. Squibb & Sons, L.L.C.5$183
Beigene USA, Inc.3$168
Bayer7$165
Eisai Inc.8$161
AVEO Pharmaceuticals, Inc.5$151
Pharmacyclics LLC, An Abbvie Company7$148
GSK6$132
Regeneron Healthcare Solutions, Inc.4$102
Pharmacosmos Therapeutics Inc.4$101
Genmab U.S., Inc.3$97
Lilly USA, LLC6$96
Taiho Oncology, Inc.4$92
Janssen Scientific Affairs, LLC1$83
ADC Therapeutics America, Inc.3$72
Array Biopharma Inc3$66
Global Blood Therapeutics, Inc.3$66
Morphosys, US Inc.3$64
Myovant Sciences Inc.3$62
Syndax Pharmaceuticals, Inc.2$62
Ipsen Biopharmaceuticals, Inc3$61
Mirati Therapeutics, Inc.2$54
Pharmaessentia USA Corporation2$52
Tersera Therapeutics LLC2$49
Gilead(2 entities)2$48
EMD Serono, Inc.2$45
Stemline Therapeutics Inc.2$44
Heron Therapeutics, Inc.3$43
Deciphera Pharmaceuticals Inc.2$42
Kyowa Kirin, Inc.2$41
Beone Medicines USA, Inc.1$32
Acrotech Biopharma Inc.2$32
Caris MPI, Inc.1$30
Blueprint Medicines Corporation1$30
Invivyd Inc1$30
Sobi, Inc1$29
EUSA Pharma (US) LLC1$28
Novocure Inc.1$28
Iovance Biotherapeutics, Inc.1$25
Myriad Genetic Laboratories, Inc.1$24
Mylan Institutional Inc.1$23
Dova Pharmaceuticals1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,554 in reported general payments places this provider in the 95th percentile of 1,562 nurse practitioner providers in Maryland.

See all nurse practitioner providers in Maryland

Medicare billing

Part B allowed, 2024
$71,511
Medicare patients
164
Services billed
2,081

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide19$332,826
EliquisApixaban16$14,143
Oxycodone Hcl17$349
Dexamethasone25$231
Acyclovir15$226
Ondansetron Hcl20$163
Prochlorperazine Maleate12$102
Gabapentin11$54

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$237$332,82619 claims
PfizerEliquis$378$14,14316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,562 nurse practitioner providers in Maryland.

Other nurse practitioner in Bethesda

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →